Abstract

β-lactam antibiotics have a well-known activity which disturbs the bacterial cell wall biosynthesis and may be cleaved by β-lactamases. However, these drugs are not active on archaea microorganisms, which are naturally resistant because of the lack of β-lactam target in their cell wall. Here, we describe that annotation of genes as β-lactamases in Archaea on the basis of homologous genes is a remnant of identification of the original activities of this group of enzymes, which in fact have multiple functions, including nuclease, ribonuclease, β-lactamase, or glyoxalase, which may specialized over time. We expressed class B β-lactamase enzyme from Methanosarcina barkeri that digest penicillin G. Moreover, while weak glyoxalase activity was detected, a significant ribonuclease activity on bacterial and synthetic RNAs was demonstrated. The β-lactamase activity was inhibited by β-lactamase inhibitor (sulbactam), but its RNAse activity was not. This gene appears to have been transferred to the Flavobacteriaceae group especially the Elizabethkingia genus, in which the expressed gene shows a more specialized activity on thienamycin, but no glyoxalase activity. The expressed class C-like β-lactamase gene, from Methanosarcina sp., also shows hydrolysis activity on nitrocefin and is more closely related to DD-peptidase enzymes. Our findings highlight the need to redefine the nomenclature of β-lactamase enzymes and the specification of multipotent enzymes in different ways in Archaea and bacteria over time.

Highlights

  • Antibiotics are part of the microorganism’s arsenal in their struggle to master microbial ecosystems [1]

  • The same is true for Archaea, in which two groups of β-lactamases are present in the majority of Archaea [4], which are not, by nature, susceptible to β-lactams since β-lactams’ target is missing in their cell wall, in which an alternative role of these enzymes may be suspected, in particular that of nuclease, ribonuclease, or glyoxalase

  • There is evidence of a transfer event of class B β-lactamase from archaea to a single bacterial group—i.e., the Flavobacteriaceae and especially the Elizabethkingia genus—which can be responsible for nosocomial infections such as neonatal meningitis, or attack of immunocompromised patients, and has an atypical antibiotic resistance profile, including resistance to thienamycin by an enzymatic mechanism

Read more

Summary

Introduction

Antibiotics are part of the microorganism’s arsenal in their struggle to master microbial ecosystems [1]. Life 2020, 10, 280 β-lactamases were present in most living organisms, including those for which there are no known β-lactam targets as seen in bacteria [4]. This is the case in humans where eighteen genes annotated as metallo-β-lactamases have been identified since 1999, some of which, known for their nuclease and/or ribonuclease activities, exhibited a β-lactamase activity [5]. In this work, we express identified archaeal class B and C β-lactamases and demonstrate multiple different activities of one archaeal enzyme appearing extremely conserved in archaea

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call